Literature DB >> 17605964

Endocrinopathy in POEMS syndrome: the Mayo Clinic experience.

Gunjan Y Gandhi1, Rita Basu, Angela Dispenzieri, Ananda Basu, Victor M Montori, Michael D Brennan.   

Abstract

OBJECTIVE: To determine the prevalence and characteristics of endocrinopathies at diagnosis of POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes) syndrome. PATIENTS AND METHODS: From January 1, 1960, through June 30, 2006, we identified 170 patients with POEMS syndrome in the Mayo Clinic dysproteinemia database. We abstracted information about endocrine abnormalities from their medical records.
RESULTS: Of the 170 patients with POEMS syndrome during the entire study period, the 64 patients seen after 2000 had more complete endocrine evaluations; of these 64 patients, 54 (84%) had a recognized endocrinopathy (38 men; median age, 50 years; interquartile range, 43-59 years). Hypogonadism was the most common endocrine abnormality; 26 (79%) of 33 men had subnormal total testosterone levels, and 10 men had gynecomastia. Among the 35 patients with measured prolactin levels, 7 men and 3 women had elevated levels. Hypothyroidism was noted in 17 men and 11 women. Abnormalities in glucose metabolism were present in 24 (48%) of 50 patients; 16 patients had impaired fasting glucose levels, and 8 were diagnosed as having diabetes. Adrenal insufficiency (defined by an abnormal response of cortisol to stimulation with standard high-dose [250 microg] synthetic adrenocorticotropic hormone) was noted in 6 of 9 patients tested. Fourteen (27%) of 51 patients tested had hypocalcemia. Twenty-nine (54%) of 54 patients had evidence of multiple endocrinopathies in the 4 major endocrine axes (gonadal, thyroid, glucose, and adrenal).
CONCLUSION: The high prevalence of endocrinopathy in our study, to our knowledge the largest published series of POEMS cases, calls for a thorough endocrine investigation in patients presenting with this syndrome.

Entities:  

Mesh:

Year:  2007        PMID: 17605964     DOI: 10.4065/82.7.836

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

Review 1.  Amyloidosis and POEMS syndrome.

Authors:  Cheng E Chee; Angela Dispenzieri; Morie A Gertz
Journal:  Expert Opin Pharmacother       Date:  2010-06       Impact factor: 3.889

Review 2.  Pancreatic involvement by plasma cell neoplasms.

Authors:  Rodrigo Lopes da Silva
Journal:  J Gastrointest Cancer       Date:  2012-06

3.  POEMS syndrome - a unique presentation of a rare paraneoplastic syndrome.

Authors:  J Livingston; C Cobiella; M A Hall-Craggs
Journal:  BMJ Case Rep       Date:  2010-12-01

4.  Clinical challenges of an oligosecretory plasma cell dyscrasia.

Authors:  Luís Rodrigues; Marta Neves; Helena Sá; Mário Campos
Journal:  BMJ Case Rep       Date:  2013-02-18

Review 5.  How I treat POEMS syndrome.

Authors:  Angela Dispenzieri
Journal:  Blood       Date:  2012-04-30       Impact factor: 22.113

6.  Coexistence of the POEMS syndrome with hepatitis B: a rare case report.

Authors:  Yılmaz Celik; Mehmet Aslan; Refah Sayın; Adem Cifci; Esra Turan Canbaz; Mehmet Emin Kucukoglu; Ahmet Cumhur Dulger
Journal:  Wien Klin Wochenschr       Date:  2014-11-21       Impact factor: 1.704

7.  Spontaneous recovery of adrenal insufficiency in POEMS syndrome.

Authors:  Khaled Ashawesh; Tarek M Fiad
Journal:  Medscape J Med       Date:  2009-01-22

8.  An unusual collision tumor comprising a prolactinoma and a plasmocytoma originating from the sellar region.

Authors:  Juan Rivera; Synnove Alves; Caterina Chiara Bianchi; Nawal Al-Mutawa; Marie Christine Guiot; Anthony Zeitouni
Journal:  Pituitary       Date:  2010-06       Impact factor: 4.107

Review 9.  Castleman Disease: A Rare Condition with Endocrine Manifestations.

Authors:  Carmen E Cervantes; Ricardo Correa
Journal:  Cureus       Date:  2015-11-17

10.  Improvement of sexual function in POEMS syndrome after combination therapy of Lenalidomide and dexamethasone.

Authors:  Hongbo Yang; Xufei Huang; Qianqian Cai; Chen Wang; Xinxin Cao; Daobin Zhou; Jian Li
Journal:  Orphanet J Rare Dis       Date:  2016-06-18       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.